Revvity (RVTY) is back in focus after recent commentary highlighted weak organic revenue growth, declining adjusted operating profits, and ongoing annual earnings per share pressure. These factors are sharpening questions about the stock’s core business performance.

At a share price of $101.22, Revvity’s recent 30-day share price return of 7.72% and 90-day gain of 19.18% suggest momentum has picked up, even though the 5-year total shareholder return is down 33.15%.

If Revvity’s recent swings have you reassessing your watchlist, it can help to compare it with other health-focused technology plays using our screener for 40 healthcare AI stocks

So with Revvity’s share price recovering but its core business still under pressure, is the stock quietly offering value at around $101, or is the market already pricing in all the future growth that matters?

Most Popular Narrative: 10.9% Undervalued

Revvity’s most followed narrative puts fair value at $113.64 per share, compared with the current $101.22 price, and uses a 8.30% discount rate to get there.

Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Want to understand why this Revvity valuation leans on margin expansion more than rapid revenue growth? The narrative focuses on a specific earnings path, a higher future profit multiple, and gradual share count shrinkage. It then connects those elements to arrive at the $113.64 fair value.

Result: Fair Value of $113.64 (UNDERVALUED)

However, there are still clear risks for Revvity, including pressure from healthcare cost controls and weaker funding for academic and government customers, which could challenge this margin focused story.

Another View: What Revvity’s P/E Says About the Stock

The first narrative says Revvity is trading below fair value, but its current P/E of 47.2x tells a tougher story. That is higher than the Global Life Sciences average of 35x and about double the 23.6x fair ratio the market could move towards. This points to valuation risk if sentiment cools.

If you lean more on earnings multiples than cash flow models, you might treat this gap as a warning sign that the Revvity stock price already reflects a lot of improvement. The key question is whether the business can deliver enough progress to support that premium or not.

Next Steps

Does this mixed picture around Revvity leave you cautious or curious? Take a closer look at the full set of data points and weigh both sides of the story with the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Revvity stock?

If Revvity has sharpened your focus on valuation and risk, do not stop here. Fresh opportunities often emerge where the numbers and story line up best.

• Spot potential mispriced opportunities early by scanning screener containing 20 high quality undiscovered gems with strong fundamentals that many investors may be overlooking.
• Prioritise sleep at night holdings by focusing on 67 resilient stocks with low risk scores that combine resilience with lower overall risk scores.
• Strengthen your core portfolio with companies from the solid balance sheet and fundamentals stocks screener (48 results) that pair financial stability with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.